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The human coronavirus NL63 (HCoV-NL63) was first
identified in the Netherlands, and its circulation in France
has not been investigated. We studied HCoV-NL63 infec-
tion in hospitalized children diagnosed with respiratory tract
infections. From November 2002 to April 2003, we evaluat-
ed 300 respiratory specimens for HCoV-NL63. Of the 300
samples, 28 (9.3%) were positive for HCoV-NL63. The
highest prevalence was found in February (18%). The main
symptoms were fever (61%), rhinitis (39%), bronchiolitis
(39%), digestive problems (33%), otitis (28%), pharyngitis
(22%), and conjunctivitis (17%). A fragment of the spike
protein gene was sequenced to determine the variety of cir-
culating HCoV-NL63. Phylogenetic analysis indicated that
strains with different genetic markers cocirculate in France.
H
uman coronaviruses (HCoVs) were first recorded in
the late 1960s; they are associated mainly with respi-
ratory tract illness but are also involved in enteric and cen-
tral nervous system diseases. They are represented by 2
prototype strains, HCoV-229E and HCoV-OC43, which
belong to antigenic groups 1 and 2, respectively. In 2003,
human coronaviruses received worldwide attention with
the emergence of severe acute respiratory syndrome
(SARS) caused by a novel coronavirus (SARS-CoV). In
2004, the increase in research on theses viruses soon led to
the discovery of 2 other human coronaviruses, HCoV-
NL63 in the Netherlands and, more recently, CoV-HKU1
in China (1–3). In March 2004, van der Hoek et al. isolat-
ed HCoV-NL63 from a nasopharyngeal aspirate taken
from a 7-month-old child hospitalized with bronchiolitis,
conjunctivitis, and fever (1). One month later, Fouchier et
al. characterized the same virus isolated from a nasal swab
that had been collected from a child with pneumonia in
April 1988 (2). Phylogenetic analysis showed that HCoV-
NL63 is a new group 1 coronavirus, most closely related to
HCoV-229E. Partial HCoV-NL63 sequences from
Australia, Japan, and Canada have been submitted to the
GenBank database, which indicates that this virus is dis-
tributed worldwide. Two retrospective studies were con-
ducted in the Netherlands, and 11 additional HCoV-
NL63–positive samples were detected from November
2000 to February 2003.
We tested for HCoV-NL63 in children with acute respi-
ratory tract infection hospitalized in Caen from November
2002 to April 2003, described symptoms associated with
this infection, and examined local strains for the genetic
variability. We also evaluated a multiplex reverse tran-
scription–polymerase chain reaction (RT-PCR) assay for
classical coronaviruses as a tool to test human coronavirus-
es (except SARS-CoV).
Materials and Methods
From November 2002 to April 2003, the virology labo-
ratory (University Hospital, Caen, France) received 1,427
respiratory samples (nasal aspirates and swabs) from
patients <20 years of age. All specimens were tested for
influenza virus Aand B; respiratory syncytial virus (RSV);
parainfluenza virus 1, 2, 3, and 4; and adenovirus by direct
or indirect immunofluorescence or virus isolation.
Samples were also tested for human metapneumovirus
(HMPV), rhinovirus, enterovirus, and HCoV 229E and
OC43 by virus isolation and RT-PCR. A total of 556 sam-
ples (39%) were positive for any of these viruses.
Symptoms indicated viral infection, as judged by the clin-
ical department; therefore, samples were not tested for
bacterial pathogens. Of the 556 positive samples, the fol-
lowing respiratory viruses were detected: RSV (37%, n =
205), rhinovirus (18%, n = 101), influenza virus A and B
(15%, n = 86), HMPV (9.7%, n = 54), and HCoV-OC43
(1.2%, n = 7); no HCoV-229E were detected.
Of the 871 negative samples, 300 (50 per month) were
tested for HCoV-NL63. These 300 samples represented
191 patients <2 years of age (64%), 46 patients 2–5 years
of age (15%), and 63 patients 6–20 years of age (21%). All
patients were hospitalized with acute respiratory tract ill-
ness. Data for 18 patients with recorded HCoV-NL63
infection were available and were examined retrospective-
ly for specific respiratory symptoms. All patients consent-
ed to having their samples tested for respiratory viruses,
including coronaviruses.
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Amsterdam, Amsterdam, the NetherlandsTwo RT-PCR assays were used to detect HCoV-NL63
in respiratory samples. RNA was extracted by using the
QIAamp Viral RNA Mini Kit (Qiagen, Hilden, Germany)
according to manufacturer’s instructions. The first RT-
PCR assay was a 1-step simple RT-PCR that amplified a
255-bp fragment of the nucleocapsid (N) gene of HCoV-
NL63 by using the following primers: N5-PCR2 (5′-
GATAACCAGTCGAAGTCACCTAGTTC-3′) and N3-
PCR2 (5′-ATTAGGAATCAATTCAGCAAGCTGTG-3′).
The second assay was a 1-step multiplex RT-PCR that
amplified the same 255-bp fragment of the N gene of
HCoV-NL63, a 574-bp fragment of the membrane (M)
gene of HCoV-229E, and a 334-bp fragment of the M gene
of HCoV-OC43 by using previously described primers
(4,5). These assays (OneStep RT-PCR kit, Qiagen) were
undertaken in 25-µL reaction volume containing 2.5 µL
RNA extract, 5 µL5 × Qiagen OneStep RT-PCR buffer, 1
µL 10 mmol/L deoxynucleoside triphosphate (dNTP), 1
µL Qiagen OneStep RT-PCR Enzyme Mix, 1.2 µL of 10
µmol/L each primer, 3 µL Qiagen OneStep RT-PCR kit Q
solution, and RNase-free water to 25 µL. The reaction was
carried out in a GeneAmp PCR system 2700 thermal
cycler (Applied Biosystems, Foster City, CA, USA) with
an initial reverse transcription step at 50°C for 30 min, fol-
lowed by PCR activation at 95°C for 15 min, 40 cycles of
amplification (30 s at 95°C, 30 s at 58°C, 1 min at 72°C),
and a final extension step at 72°C for 10 min. Each RT-
PCR test included water controls that were treated identi-
cally to the virus samples throughout and was performed
with usual precautions to avoid contamination.
RT-PCR products were subject to electrophoresis on an
agarose gel, stained with ethidium bromide, and visualized
under UV light. The comparative analytical sensitivities of
these simple and multiplex RT-PCR assays were previous-
ly studied on prototype strains by analyzing serial 10-fold
dilutions of positive control for HCoVs NL63, OC43, and
229E. The analytical sensitivity was equivalent to detect
HCoV-OC43, the multiplex assay was more sensitive (by
one 10-fold dilution) to detect HCoV-229E, and less sensi-
tive (by one 10-fold dilution) to detect HCoV-NL63 (data
not shown). No cross-reaction of these tests was observed
between these coronaviruses. Samples that were positive
for HCoVs NL63, 229E, and OC43 were confirmed by
using a DNA enzyme immunoassay (GEN-ETI-K DEIA,
Sorin, Saluggia, Italy) carried out as recommended by the
manufacturer with original probes previously described for
HCoVs 229E and OC43 and the following probe defined
in the N gene for HCoV-NL63: 5′-(Biotin)CCTCTTTCT-
CAACCCAGGGCTGATA-3′ (4). A third RT-PCR assay
was carried out on 12 HCoV-NL63–positive samples
amplifying a 523-bp fragment with spike (S) gene–specif-
ic primers NL63-S-sens (position 22557–22582: 5′-
ACCGCTGTTAATGAGTCTAGATATG-3′) and NL63-S-
antisens (position 23043–23063: 5′-GTCCTGCTATACG-
GCTTGAA-3′). This assay was performed essentially as
described above. The RT-PCR products were purified by
using ExoSAP-IT (USB Corporation, Cleveland, OH,
USA) and sequenced with the primers by using the CEQ
Dye Terminator Cycle Sequencing Quick Start Kit on a
CEQ 8000 Genetic Analysis System (Beckman Coulter,
Fullerton, CA, USA). The nucleotide sequences of the par-
tial S gene (GenBank accession nos. AY994243–
AY994254) were compared with the 2 prototype HCoV-
NL63 sequences available in GenBank (NL63-
Amsterdam1: NC005831 and NL: AY518894). Both
nucleotide and predicted amino acid sequence alignments
were prepared by using ClustalX version 1.83. The phylo-
genetic trees were constructed by using HCoV-229E as an
outgroup.
Results
HCoV-NL63 was detected in 28 (9.3%) of the 300 sam-
ples evaluated from November 2002 to April 2003.
Twenty-two samples were positive for HCoV-NL63 by
both simple and multiplex RT-PCR (Figure 1). Discordant
results were found for the remaining 6 samples: 3 were
positive only in simple RT-PCR, and 3 were positive only
in multiplex RT-PCR. These discordant samples were con-
trolled by using the same methods from the RNA extrac-
tion product; the results obtained were identical. The
specificity of the RT-PCR products under UV was con-
firmed by hybridization. Multiplex RT-PCR identified 3
samples with HCoV-OC43 and 1 sample with both HCoV-
NL63 and HCoV-OC43. The 28 HCoV-NL63–positive
samples were obtained from 18 patients <2 years of age
(65%), 4 patients 2–5 years of age (14%), and 6 patients
6–15 years of age (21%). The age distribution of the
patients infected by HCoV-NL63 was identical to the age
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Figure 1.  Ethidium bromide stain of 2% agarose gel showing
reverse transcription-polymerase chain reaction (RT-PCR) prod-
ucts of human coronaviruses (HCoVs). A) Simple 1-step RT-PCR
(HCoV-NL63, gene N): lane 1, size markers (100 bp); lane 2, neg-
ative control RT-PCR mix; lane 3, positive control HCoV-NL63. B)
Multiplex 1-step RT-PCR (HCoVs NL63, OC43, 229E): lane 4, size
markers (100 bp); lane 5, negative control RT-PCR mix; lane 6,
positive control HCoV-NL63; lane 7, positive control HCoV-OC43;
lane 8, positive control HCoV-229E; lane 9, mix of 3 positive con-
trol HCoVs (NL63, OC43, and 229E).distribution of the sample. Positive specimens were col-
lected throughout the study period; no epidemic was
observed. The temporal distribution of HCoV-NL63 infec-
tion is shown in Figure 2.
All patients included in this study had a respiratory tract
illness. The medical reports of 18 patients with HCoV-
NL63–positive samples were retrospectively examined,
and the following symptoms were noted: fever (61%, n =
11), rhinitis (39%, n = 7), lower respiratory tract illness
(bronchiolitis, pneumonia [39%, n = 7]), digestive prob-
lems (diarrhea and abdominal pain [33%, n = 6]), otitis
(28%, n = 5), pharyngitis (22%, n = 4), and conjunctivitis
(17%, n = 3). One patient had severe underlying disease
(congenital immunodeficiency) and had upper respiratory
tract illness with fever, another had a family history of
atopic allergy, and pneumonia was diagnosed. Overall,
more than one third of the patients infected by HCoV-
NL63 had severe lower respiratory tract infection (6 bron-
chiolitis and 1 pneumonia). All of them recovered
completely.
To determine if the isolates from France contain differ-
ent genetic markers, we sequenced a part of the S protein
gene of 12 isolates for molecular analysis. The phylogenet-
ic analysis shows that the isolates from France are a diver-
gent group containing sequences with different markers.
One isolate (23034101) had characteristics of an outlier
(Figure 3A). The phylogenetic analysis of the predicted
amino acid sequence also shows that this isolate is an out-
lier (Figure 3B). However, the branches of this tree are
based on only 1 amino acid difference. Care should be
taken because of the limited informative sites in the
sequence.
Discussion
A number of viruses cause respiratory infections, and
many infections cannot be attributed to any known
pathogen (6). This fact may be because some detection
methods lack sensitivity, because some respiratory viruses
are not systematically tested for, or because some
pathogens are not yet identified. Of the 4 novel agents,
HMPV, SARS-CoV, HCoV-NL63, and CoV-HKU1, iden-
tified recently, 3 were coronaviruses (1,3,7–9).
Coronaviruses infect many species of mammals and birds,
they possess the largest genome of all RNA viruses (≈30
kb), and they have a high frequency of recombination. In
addition, the potential to infect other species has been
described for bovine coronavirus and is suspected to have
caused the SARS outbreak (10,11). Therefore, coron-
aviruses represent a potential major infectious agent in
humans. Based on genotypic and serologic characteristics,
coronaviruses were divided into 3 distinct groups: with
HCoVs 229E and NL63 in group 1 and HCoVs OC43 and
HKU1 in group 2. SARS-CoV is not definitively assigned
to any of these groups. However, an early split-off of
SARS-CoV from the group 2 lineage was suggested (12).
Until recently, only the HCoVs 229E and OC43 and
SARS-CoV have been thoroughly studied. As suggested
by epidemiologic surveys conducted in the 1970s, human
coronaviruses are distributed worldwide and circulate dur-
ing seasonal outbreaks (13–15). In this study, we deter-
mined whether this is also the case for HCoV-NL63.
Furthermore, we looked at the symptoms of a HCoV-NL63
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Figure 2. Number of human coronavirus NL63-positive samples
per month. Fifty samples from patients hospitalized for acute res-
piratory symptoms were tested each month.
Figure 3. A) Phylogenetic analysis of a 523-bp region of the par-
tial spike gene of 12 human coronavirus (HCoV)-NL63 isolates
from France. To construct the trees, the 2 prototype strains
NL63-Amsterdam1 and NL-AY518894 were included. HCoV-
229E is used as an outgroup. A) Nucleotide sequence align-
ments created with ClustalX 1.83; bootstrap values >70 are
indicated. B) Predicted amino acid sequences; bootstrap values
>50 are indicated.infection and the heterogeneity of the virus isolate circulat-
ing in France. In this study, 9.3% of the samples were pos-
itive for HCoV-NL63. These results suggest that
HCoV-NL63 can frequently cause infections, particularly
in young children.
Because of availability, only samples that tested nega-
tive for other respiratory viruses were included in this
study. Consequently, we could not identify co-infections.
Nevertheless, by using multiplex RT-PCR, which simulta-
neously detected the classical human coronaviruses
(OC43, 229E, and NL63), we detected 1 co-infection by
HCoVs NL63 and OC43 and 3 HCoV-OC43–positive
samples. These additional cases of HCoV-OC43 infection
in our patients can be explained by the fact that multiplex
RT-PCR was performed directly on respiratory samples,
whereas in previous routine tests, samples were first
instilled into a cell culture system (HUH7 cell line) and
RT-PCR was then performed on cell culture supernatant.
Detecting human respiratory coronaviruses requires
molecular techniques because of difficulties in virus cul-
ture and lack of an assay to detect intracellular antigens or
others serologic assay. A multiplex RT-PCR is therefore a
useful tool to simultaneously test for various HCoVs from
a clinical sample. This study showed that the clinical sen-
sitivity of multiplex RT-PCR was equivalent to simple RT-
PCR, allowing clinical studies and routine testing.
No HCoV-229E was detected in samples. HCoVs 229E
and NL63 both belong to antigenic group 1. The percent-
age amino acid sequence identities between the S, M, and
N proteins of HCoVs NL63 and 229E are 54.7%, 61.5%,
and 43.2%, respectively (2). A cross-protective immune
response could explain why these 2 human coronaviruses
do not circulate at the same time. We detected HCoV-
NL63 in respiratory specimens in February with a frequen-
cy of 18%. These results correlate with the fact that human
coronaviruses circulate primarily in the winter. However,
HCoV-NL63 was found in nasal aspirates each month of
our study.
The clinical symptoms associated with HCoV-NL63
still need to be determined. In the patients in our study,
symptoms included not only respiratory symptoms but
also lower respiratory tract diseases such as bronchiolitis,
bronchitis, and pneumonia. Human coronaviruses, except
SARS-CoV, generally cause disease much like the com-
mon cold, but they have also been associated with more
severe lower respiratory tract conditions, especially in frail
patients (4,16). Whether HCoV-NL63 is also responsible
for coldlike illnesses in healthy adults, as has been
described for HCoVs 229E and OC43, must be deter-
mined. The same can be said about the very recently
described coronavirus CoV-HKU1. This virus was identi-
fied in a 71-year-old patient with chronic obstructive air-
way disease who was hospitalized with pneumonia (3).
Digestive problems were noted in approximately one
third of patients. No clear evidence exists that human coro-
naviruses, except SARS-CoV, cause enteric illness, but
previous studies have suggested that these viruses may be
involved in enteric diseases (17–20). Further studies must
be conducted to detect coronaviruses in stool samples and
clarify the origin of these digestive symptoms.
The S protein of coronaviruses is a major determinant
of cell tropism and pathogenicity and a major inducer of
neutralizing antibodies (21). Furthermore, heterogeneity of
the S gene has been observed for different HCoV-NL63
strains. We amplified part of the S gene to study the vari-
ability of our isolates. Phylogenetic analysis showed that
several different isolates are cocirculating in France, simi-
lar to the situation in the Netherlands, Australia, Canada,
and Belgium.
In conclusion, HCoV-NL63 can be found in patients
with upper and lower respiratory tract illness, particularly
in hospitalized children. This observation is the first of
HCoV-NL63 infection in France, and several isolates of
HCoV-NL63 were found to circulate in our country. The
sensitive multiplex RT-PCR for the HCoVs NL63, 229E,
and OC43 that we developed is a useful tool to facilitate
the routine detection of these pathogens.
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